Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
Introduction: Ductal adenocarcinoma of the prostate is a rare subtype of prostate cancer that arises from the ducts of the prostate gland. It is characterised by distinct histological features and a more aggressive clinical course. Neuroendocrine differentiation within this subtype is associated with a more aggressive phenotype and can lead to resistance to conventional androgen deprivation therapies.
Conference:
Presenting Author:
Authors: Zerrouk D, Boukerzaza I, Laouar N, Kassama Z, Mansouri F,
Keywords: neuroendocrine prostate cancer, progression, multidisciplinary approach,
Introduction: Global research on neuroendocrine differentiation (NED) in carcinomas remains limited, despite its distinct clinical features, disease progression, pathology, treatment outcomes, and poor prognosis. At the 2023 ENETS Conference, we presented our findings on NED in gastric cancer and colorectal cancer. However, more studies are essential to better comprehend NED's clinical and epidemiological aspects.
Conference:
Presenting Author:
Keywords: Neuroendocrine differentiation, breast cancer, lung cancer, esophageal cancer, prostate cancer,
#3806 Epidemiologic study of neuroendocrine differentiation in different carcinomas
Introduction: Carcinomas with neuroendocrine differentiation (NED) are characterized by clinical manifestations, pathological changes, treatment responses and poor prognosis. But there are few studies around the world currently. Further analysis of large clinical samples is still needed to reveal its biological characteristics and clarify the diagnosis and treatment of NED.
Conference:
Presenting Author:
Keywords: Neuroendocrine differentiation, individualized treatment, colorectal cancer, gastric cancer,
#3363 Neuroendocrine prostate cancer: About 4 cases
Introduction: Neuroendocrine tumors of the prostate are rare entities with a very poor prognosis. They can be pure (small or large cell neuroendocrine carcinoma) or mixed. They do not express prostate specific antigen (PSA) or the androgen receptor. Their treatment is based only on chemotherapy based on platinum for the advanced forms.
Conference:
Presenting Author:
Authors: Kehili H, Bengueddache A, Boumansour N, Kaid M, Benabdellah H,
Keywords: neuroendocrine prostate, poor prognosis,
Introduction: Neuroendocrine differentiation (NED) of metastasised castrate-resistant prostate cancer (mCRPC) is normally associated with poor prognosis.
Conference: 18th Annual ENETS Concerence (2021)
Presenting Author: Prasad V
Authors: Grunert M, Miksch J, Steinacker J, Zengerling F, Glatting G,